mosunetuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (humanized origin); tumor 5700 1905409-39-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • mosunetuzumab
  • lunsumio
  • RO7030816
  • RG7828
  • BTCT4465A
Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody targeting CD20-expressing B-cells. It is a conditional agonist; targeted B-cell killing is observed only upon simultaneous binding to CD20 on B-cells and CD3 on T-cells. Engagement of both arms of mosunetuzumab results in the formation of an immunologic synapse between a target B cell and a cytotoxic T cell leading to T-cell activation. Subsequent directed release of perforin and granzymes from T-cell activation through the immunologic synapsis induce B-cell lysis leading to cell death.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 3, 2022 EMA Roche Registration GmbH
Dec. 22, 2022 FDA GENENTECH INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 377.64 75.08 77 644 27896 90599830
Vasogenic cerebral oedema 178.26 75.08 26 695 1264 90626462
Disease progression 164.38 75.08 57 664 156558 90471168
Neurological symptom 134.90 75.08 26 695 6821 90620905
Diffuse large B-cell lymphoma recurrent 131.71 75.08 23 698 3503 90624223
Disorientation 86.75 75.08 26 695 44088 90583638
Therapy partial responder 84.81 75.08 22 699 22021 90605705

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 215.65 58.14 57 432 44470 42576376
COVID-19 81.97 58.14 35 454 115913 42504933
COVID-19 pneumonia 64.05 58.14 19 470 21594 42599252

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 517.21 60.04 126 1147 70180 110517846
Disease progression 182.96 60.04 77 1196 243957 110344069
Vasogenic cerebral oedema 153.90 60.04 26 1247 2232 110585794
COVID-19 pneumonia 124.52 60.04 36 1237 37107 110550919
Diffuse large B-cell lymphoma recurrent 109.75 60.04 23 1250 6276 110581750
Neurological symptom 103.79 60.04 26 1247 15582 110572444
Neutropenia 103.53 60.04 60 1213 374560 110213466
COVID-19 100.38 60.04 51 1222 245009 110343017
Malignant neoplasm progression 76.23 60.04 38 1235 174529 110413497
Disorientation 65.14 60.04 26 1247 70645 110517381
Therapy partial responder 61.42 60.04 21 1252 37040 110550986

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX25 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsed or refractory follicular lymphoma indication 55150002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
B-lymphocyte antigen CD20 Surface antigen UNKNOWN DRUG LABEL

External reference:

IDSource
CHEBI:757234 CHEBI
CHEMBL4297788 ChEMBL_ID
C000731929 MESH_SUPPLEMENTAL_RECORD_UI
12298 IUPHAR_LIGAND_ID
DB15434 DRUGBANK_ID
278181000202107 SNOMEDCT_US
4041943 VANDF
C4763385 UMLSCUI
10621 INN_ID
D11463 KEGG_DRUG
364475 MMSL
41159 MMSL
d09958 MMSL
019149 NDDF
LDJ89SS0YG UNII
2625122 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lunsumio HUMAN PRESCRIPTION DRUG LABEL 1 50242-142 CONCENTRATE 30 mg INTRAVENOUS BLA 31 sections
Lunsumio HUMAN PRESCRIPTION DRUG LABEL 1 50242-159 CONCENTRATE 1 mg INTRAVENOUS BLA 31 sections
Lunsumio Velo HUMAN PRESCRIPTION DRUG LABEL 1 50242-177 INJECTION 5 mg SUBCUTANEOUS BLA 30 sections
Lunsumio Velo HUMAN PRESCRIPTION DRUG LABEL 1 50242-201 INJECTION 45 mg SUBCUTANEOUS BLA 30 sections